JMIR Formative Research

View query in Help articles search

Field

e.g. mhealth

Operator

Field

Criteria

e.g. mhealth

Search Results (1 to 10 of 16 Results)

Download search results: CSV END BibTex RIS

Sort by:

Tobacco Use, Risk Perceptions, and Characteristics of Adults Who Used a Heated Tobacco Product (IQOS) in the United States: Cross-Sectional Survey Study

The US Food and Drug Administration (FDA) authorized the marketing of THS in the United States in April 2019. Subsequently, it granted a modified risk tobacco product (MRTP) order in July 2020 authorizing the use of the following reduced exposure claim: “AVAILABLE EVIDENCE TO DATE: The IQOS system heats tobacco but does not burn it. This significantly reduces the production of harmful and potentially harmful chemicals.

Hui G Cheng, Brendan Noggle, Andrea R Vansickel, Edward G Largo, Pierpaolo Magnani

JMIR Form Res 2025;9:e57398

Download Citation: END BibTex RIS

Download PDF Download XML

Concerns Over Vuse e-Cigarette Digital Marketing and Implications for Public Health Regulation: Content Analysis

Vuse Solo was also the first e-cigarette to be authorized by the US Food and Drug Administration (FDA) through the premarket tobacco product application (PMTA) process [7,8], with the FDA issuing this first marketing granted order (MGO) for Vuse Solo in October, 2021. The law requires companies to first obtain marketing authorization from the FDA based on a previously submitted PMTA before coming to market [9,10].

Eileen Han, Lauren K Lempert, Francesca Vescia, Bonnie Halpern-Felsher

JMIR Form Res 2024;8:e54661

Download Citation: END BibTex RIS

Download PDF Download XML

Public Perceptions of the Food and Drug Administration's Regulatory Authority Over Synthetic Nicotine on Twitter: Observational Study

The third category was “government or FDA mistrust,” as users did not believe the FDA should be regulating these products and that there was a partnership between the government and big tobacco companies. The last category was “call to promote opposition against the bill,” which were tweets calling for people to text senators to show opposition. Based on the codebook developed, the remaining 764 tweets were single-coded by 2 coders (JZ and JF).

Jonathan Zou, Juan Ramon Feliciano, Zidian Xie, Dongmei Li

JMIR Form Res 2024;8:e56371

Download Citation: END BibTex RIS

Download PDF Download XML

Public Perceptions and Discussions of the US Food and Drug Administration's JUUL Ban Policy on Twitter: Observational Study

On January 2, 2020, the US Food and Drug Administration (FDA) released the e-cigarette flavor enforcement policy to prohibit the sale of all flavored cartridge-based e-cigarettes, except for menthol and tobacco flavors. Twitter (subsequently rebranded as X) users’ perceptions of e-cigarettes became more negative after the announcement [13].

Pinxin Liu, Xubin Lou, Zidian Xie, Ce Shang, Dongmei Li

JMIR Form Res 2024;8:e51327

Download Citation: END BibTex RIS

Download PDF Download XML

Peer Review for “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

In this manuscript titled “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis” [1], the authors analyzed over 18 million reports from the Food and Drug Administration (FDA) Adverse Event Reporting System, among which over 17,000 cases were identified to have increased possibility of thyroid hyperplasia and neoplasm when taking glucagon-like peptide-1 (GLP-1) receptor

Anonymous

JMIRx Med 2024;5:e59120

Download Citation: END BibTex RIS

Download PDF Download XML

Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

In this manuscript titled “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis” [2], the authors analyzed over 18 million reports from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), among which over 17,000 cases were identified to have increased possibility of thyroid hyperplasia and neoplasm when taking glucagon-like peptide-1 (GLP-1

Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan

JMIRx Med 2024;5:e58273

Download Citation: END BibTex RIS

Download PDF Download XML

Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

The increased popularity of GLP-1 RAs and the unsettled association of thyroid hyperplasias and neoplasms prompted further investigation into the most recent US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data sets. In this study, we evaluated thyroid hyperplasia and neoplasm–related AEs that are reported as being associated with GLP-1 RA monotherapy when compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors monotherapy.

Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan

JMIRx Med 2024;5:e55976

Download Citation: END BibTex RIS

Download PDF Download XML